Evidence map›Paper›PMID 35056533›Full record

ArticleMicroorganisms2021

Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population.

George Krashias, Elie Deeba, Astero Constantinou, Maria Hadjiagapiou, Dana Koptides, Jan Richter, Christina Tryfonos, Stavros Bashiardes, Anastasia Lambrianides, Maria A Loizidou and 3 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

George KrashiasCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
Elie DeebaDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Astero ConstantinouDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Maria HadjiagapiouCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
Dana KoptidesDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Jan RichterDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Christina TryfonosDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Stavros BashiardesDepartment of Molecular Virology, The Cyprus Institute of Neurology and Genetics, Nicosia 2371, Cyprus.
Anastasia LambrianidesCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
Maria A LoizidouCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.ORCID 0000-0003-4503-7758
Andreas HadjisavvasCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.ORCID 0000-0002-5636-0799
Mihalis I PanayiotidisCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.ORCID 0000-0002-1450-3552
Christina ChristodoulouCyprus School of Molecular Medicine, Nicosia 2371, Cyprus.
Cyprus Institute of Neurology and Genetics · CY

Funding

Cyprus Institute of Neurology and Genetics 2019-80B
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit its second year and continues to damage lives and livelihoods across the globe. There continues to be a global effort to present serological data on SARS-CoV-2 antibodies in different individuals. As such, this study aimed to characterize the seroprevalence of SARS-CoV-2 antibodies in the Cypriot population for the first time since the pandemic started. Our results show that a majority of people infected with SARS-CoV-2 developed IgG antibodies against the virus, whether anti-NP, anti-S1RBD, or both, at least 20 days after their infection. Additionally, the percentage of people with at least one antibody against SARS-CoV-2 in the group of volunteers deemed SARS-CoV-2 negative via RT-PCR or who remain untested/undetermined (14.43%) is comparable to other reported percentages worldwide, ranging anywhere from 0.2% to 24%. We postulate that these percentages reflect the underreporting of true infections in the population, and also show the steady increase of herd immunity. Additionally, we showed a significantly marked decrease in anti-NP IgG antibodies in contrast to relatively stable levels of anti-S1RBD IgG antibodies in previously infected individuals across time.

Indexed as

IgG antibodynucleocapsid (N) proteinSARS-CoV-2seroprevalenceSpike 1 receptor binding protein

Identifiers

PMID35056533
PMCPMC8777616
OpenAlexW4205778844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.